02- CLINICAL DEVELOPMENT

Another Phase III Trial In AD Going ‘Gungho’!

Apparently 11 patients treated is sufficient now for developers to go straight into a big Phase III trials Sounds like Lilly all over again! Whatever happened to classic drug development? Obviously the review article I did with Bengt Winblad and Julian Gray didn’t put any one off >> http://www.fiercebiotech.com/biotech/early-win-means-phase-3-test-way-for-axovant-s-dementia-drug?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTTJRNE1UQTNNV1prWVdRMCIsInQiOiI3UlpZdEFXMTRldkIySSt3WFQyaitKVGl2YkNENWRNY0V1eUtESjJ5ellmQVVmaURvWXNIbmppYmxjSmZUczA3TkwxejRZMnpvSmlXdTExZk1aYUFIWG1JM1RTT0d4ZGpaR0dGckVybVdMQTgrWDc0VFdBN0ZcLzdrcllkSlh3UjgifQ%3D%3D

Read More

War On AD?

News items in the Times over the last 2 days. Seems like the disease is still winning for all our efforts >>> http://www.thetimes.co.uk/past-six-days/2017-01-30/news/drug-failure-deals-blow-to-dementia-sufferers-ll27jd65r http://www.thetimes.co.uk/edition/news/century-long-war-on-alzheimers-edges-towards-uncertain-endgame-n9mm9k0jk

Read More

Challenges To Conducting Clinical Trials

Not a formal survey but this poll shows what concerns there are for clinical trials Complexity / Regulations / Costs / Patient access / Staff? / Technology / Oversight / New drugs Bring it on! 🙂 >>> http://www.clinicaltrialpartnershipsblog.com/2016/11/report-8-biggest-challenges-facing.html?utm_source=PCT+Blog+Registrations&utm_campaign=8ce0a92a2a-PCT_Content12_bloglist_top5_04_01_17&utm_medium=email&utm_term=0_81d996f2c9-8ce0a92a2a-132135521&goal=0_81d996f2c9-8ce0a92a2a-132135521

Read More

Another New Treatment For AD?

But this one is novel – wearable tech Flickering light stimulation! >>>> Non-invasive visual stimulation to treat Alzheimer’s disease

Read More

Botox for Depression!

As an injection as well! >>> http://www.fiercepharma.com/marketing/allergan-eyes-depression-as-blockbuster-botox-next-big-stage?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTVRKbU0yVmlOakV6WlRNMyIsInQiOiI1UytxY3FlVmd6cWcwSldsbHptMTFHUFV3R1hlQTd3ZVBtNExXY2dSYWF2SnhCb0dOUlk2NGJtSlA4MENXMFg2eCtITm40Qzd4WGltK3c0Y2FPR2tjYmdvb3FDdmVpZWNRNDZTSXRSQlRxQTBseDZCVHczUmlHUlwvbkQrcVFQK3QifQ%3D%3D

Read More

Here We Go Again!

Lilly are off again only one day after the announcement of the failure of solanezumab at CTAD When will they learn protein plaques is not the answer!!! >>> http://www.fiercebiotech.com/biotech/after-ph3-failures-lilly-signs-new-alzheimer-s-drug-pact-astrazeneca

Read More

Recent Big Failure For Biotech

Arrowheads failure in Hep B with ARC-520 in primates is a reminder that although there is loads of promise for new developments  – Not everything works! >>>> http://www.fiercebiotech.com/biotech/arrowhead-snaps-after-trial-hold-as-it-targets-major-layoffs-ditches-programs?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiTURReE9XRXdOREEwWlRkaSIsInQiOiJqdGYwTStIVVc2ZCtYZGhHZm82VzREMGhqb0R5SmxTeFFzK2hrNGN0czdnTUk2b2NFaWtFajI0XC9TWlVETVwvSEZZazhjMnlLODIrTnpuV3hmZTU0VmZ4SjdUQTdwY2ZXMHdDRkh5UENwYzNZPSJ9

Read More

Ergomed CRO Discounts Costs Of Development

The Ergomed CRO services provider model seems to involve discounting the clinical management costs for shares in the development rights of the new compound Sounds like bit of an extreme and risky way of getting business to me >>> http://www.proactiveinvestors.co.uk/companies/news/124711/ergomed-s-hybrid-strategy-gives-it-plenty-of-ammo-124711.html

Read More